Pasithea Therapeutics Corp (KTTA) Stock Analysis

Pasithea Therapeutics Corp (KTTA) is a publicly traded company in the HEALTHCARE sector. It trades at $0.65, carries a market capitalization of $23.90M. This page summarizes the public market data, fundamentals, and frequently asked questions for KTTA, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Pasithea Therapeutics Corp currently has a Bullish sentiment score of 0.46.

About Pasithea Therapeutics Corp

Pasithea Therapeutics Corp. (KTTA) is a Miami Beach-based biopharmaceutical company dedicated to developing innovative therapeutics targeting psychiatric and neurological disorders through psychedelic compounds. The company aims to address significant unmet medical needs, positioning itself as a leader within the burgeoning field of mental health treatments. With a robust commitment to clinical research and development, Pasithea's proprietary platform not only seeks to enhance patient outcome...

GNG Research Analysis

GNG Research scores Pasithea Therapeutics Corp (KTTA) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for KTTA.

Frequently Asked Questions

Does KTTA pay dividends?

Pasithea Therapeutics Corp (KTTA) does not currently pay a regular dividend.

What is KTTA's market cap?

Pasithea Therapeutics Corp (KTTA) has a market capitalization of $23.90M with a current stock price of $0.65.